lunes, 18 de noviembre de 2019

The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients. - PubMed - NCBI

The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients. - PubMed - NCBI



 2019 Nov 10. doi: 10.1002/cam4.2682. [Epub ahead of print]

The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.

Cai D1,2Hu C1,2Li L1,2Deng S1,2Yang J1,2Han-Zhang H3Li M1,2,4,5.

Author information


1
Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
2
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
3
Burning Rock Biotech, Guangzhou International Biotech Island, Guangzhou, China.
4
Center for Molecular Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
5
Key Laboratory of Molecular Radiation Oncology of Hunan Province, Changsha, Hunan, China.

Abstract

OBJECTIVE:

KRAS mutation plays a critical role in the initiation and development of non-small cell lung cancer (NSCLC). KRAS-mutant patients exhibit diverse response to chemotherapy. KRAS co-mutation subtypes and their prognosis value in advanced Chinese NSCLC patients remain largely elusive.

METHODS:

A total of 1126 Chinese advanced NSCLC patients from Xiangya hospital were screened by capture-based ultra-deep sequencing for KRAS mutation between January 2015 and December 2016. Survival analyses were performed using Kaplan-Meier analysis.

RESULTS:

Among the patients screened, 84 cases were detected with KRAS mutation (7.5%). All of them were non-squamous NSCLC and received pemetrexed plus platinum as the first-line treatment. The most frequent KRAS co-mutation genes were TP53 (29%), TP53/LKB1 (19%), and LKB1 (14%). Our data revealed that patients with KRAS co-mutation had poorer prognosis in comparison with those harboring single KRAS mutation. Furthermore, patients with KPL (KRAS mutated with TP53 and LKB1) subtype, which was a novel subtype, had the shortest progression-free survival (PFS) in all types of KRAS co-mutation patients (P < .0001). The PFS and overall survival (OS) of patients with KRASG12D mutation were inferior than those with KRASG12C mutation or KRASG12V mutation. Patients in KRASG>T type had significantly longer survival than those in KRASG>C type or KRASG>A type.

CONCLUSION:

Our study revealed that concurrent genomic alterations can further stratify KRAS-mutant lung adenocarcinoma patients into various subgroups with distinctive therapeutic responses and differential survival outcomes. The KPL is a novel and less responsive subtype among KRAS-mutated NSCLC, and further investigation of effective treatment for this subtype is warranted.

KEYWORDS:

KRAS ; Chinese; co-mutation; heterogeneity; non-small cell lung cancer

PMID:
 
31709742
 
DOI:
 
10.1002/cam4.2682
Free full text

No hay comentarios:

Publicar un comentario